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ABSTRACT
Background and Objectives: The factors related to the progression of mild aortic stenosis (AS) remain unknown. We 
wanted to evaluate the long-term outcomes and predictors of echocardiographic progression in patients with mild AS. Sub-
jects and Methods: We prospectively included 103 consecutive asymptomatic patients (62.1±11.9 years, 31 males) with 
mild AS. Mild AS was defined as aortic valve (AV) thickening accompanied by a peak aortic jet velocity (AV Vmax) ≥2.0 and 
<3.0 m/sec, and rapid progression of AS was defined as an average annual increase in the AV Vmax ≥0.2 m/sec, and cardiac 
events were defined as cardiac death or AV replacement. Results: During a median echocardiographic follow-up time of 6.0 
years, the average change in the AV Vmax was 0.08±0.10 m/sec per year. The rate of progression was significantly associated 
with age, moderate-to-severe AV calcification and the baseline AV Vmax, but not with the serum cholesterol level. The base-
line AV Vmax (2.6±0.3 m/sec vs. 2.2±0.3 m/sec, respectively, p<0.001) and the incidence of moderate-to-severe AV calcific-
ation (92.9% vs. 36.5%, respectively, p<0.001) were significantly higher in the rapid progression group than in the slow pro-
gression group. The 7-year cardiac event-free survival rate was lower in the rapid progression group than in the slow pro-
gression group (87.5±8.3% vs. 100%, respectively). Conclusion: The progression of AS was slower than expected and it was re-
lated to age, the baseline AV Vmax and AV calcification. Because of the marked individual variability in progression, the pa-
tients showing rapid progression of AS need closer follow-up. (Korean Circ J 2011;41:649-653)
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Introduction
Aortic stenosis (AS) is a gradually progressive disease that 
is characterized by an increase in calcium deposition and this 
leads to progressive narrowing of the aortic valve (AV). AS 
is mediated by a chronic inflammatory disease process that is 
very similar to that seen in atherosclerosis,
1-4) but lipid-lower-
ing therapy did not slow the progression of AS in the SAL-
TIRE, SEAS or ASTRONOMER trials.
5-7) However, the cited 
trials may have targeted patients in whom the disease was too 
advanced for lipid-lowering therapy to be effective,
8) or in 
whom atherogenesis was not the central pathogenic process 
in AS.
9) Even in a study that included patients with mild and 
moderate AS,
10) hypercholesterolemia was not associated with 
adverse events, whereas the extent of AV calcification and the 
peak aortic jet velocity were associated with poor outcomes. 
Because the progression of AS is variable and this is influ-
enced by the valve morphology
11) and the degree of steno-
sis,
12) a prospective study is needed that will evaluate the nat-
ural history and predictors of progression in patients with 
mild AS. Using our prospectively collected registry data on 
patients with AS,
11) we evaluated the long-term outcomes and 
predictors of echocardiographic progression in patients with 
mild AS.
Subjects and Methods
Study population
A prospective registry was created in our hospital, using a 650   Progression of Mild Aortic Stenosis
standard case report form, and this included all the consecu-
tive patients with AS and who were undergoing echocardio-
graphy. The case report forms, including information on the 
patient demographics, the clinical presentation and the echo-
cardiographic data, are stored in an electronic database.
11) The 
clinical and echocardiographic follow-up data on the pati-
ents has been collected annually. From 2001 to 2003, a total of 
103 consecutive asymptomatic patients (62.1±11.9 years; 31 
males) with mild AS were enrolled. Mild AS was defined as 
AV thickening accompanied by a peak aortic jet velocity ≥2.0 
and <3.0 m/sec. In agreement with the exclusion criteria of 
the SEAS trial,
6) patients were excluded if they had other sig-
nificant valvular disease, moderate or severe aortic regurgi-
tation, a left ventricle (LV) ejection fraction (EF) <50%, re-
gional wall motion abnormalities, established coronary, ce-
rebral and/or peripheral vascular disease, renal insufficiency 
or uncontrolled endocrine, metabolic or liver disease.
Informed consent was obtained from each patient and the 
study protocol was approved by the Ethics Committees of 
our institutions.
Echocardiographic evaluation
All the patients underwent annual comprehensive two-di-
mensional and Doppler echocardiographic follow-up exam-
inations using Hewlett-Packard Sonos 2500 or 5500 imaging 
systems equipped with 2.5-MHz transducers (Hewlett-Pack-
ard, Andover, MA, USA). The end-systolic dimension, end-
diastolic dimension and end-diastolic interventricular septal 
and po-sterior wall thickness of the LV were measured from 
the pa-rasternal M-mode acquisitions. The end-systolic vol-
ume, end-diastolic volume and EF of the LV were obtained 
using the biplane Simpson method,
13) and the LV mass was 
calculated with the formula validated by Devereux et al.
14) On 
the two-dimensional imaging of the AV in the parasternal sh-
ort axis view, the etiology of AS was defined as bicuspid if two 
leaflets were clearly visible during systole, as rheumatic if com-
missural fusion and mitral valve involvement were observed 
and as degenerative if thickening and calcification of the leaf-
lets were notable.
15) AV calcification was graded as mild when 
a single spot or scattered small spots of echo brightness were 
observed, as moderate when the calcified mass involved one 
or two leaflets and as severe when there was extensive thick-
ening and the calcified mass involved all the leaflets.
16) The ma-
ximal aortic jet velocity (AV Vmax) was recorded using the 
window (apical, right parasternal, or suprasternal) that yield-
ed the highest velocity signal. The maximal and mean pres-
sure gradients across the AV were calculated using a modified 
Bernoulli equation, and the AV area was estimated from the 
continuity equation using the LV outflow tract diameter and 
the flow velocity.
15) For patients in sinus rhythm, the data from 
3 cardiac cycles were averaged. However, for patients with 
irregular rhythm such as atrial fibrillation, 5 cycles were aver-
aged to ensure the accuracy of the results. The change of the 
AV Vmax was calculated during annual echocardiographic 
follow-up, and the average change of the AV Vmax was deter-
mined for each patient. A rapid progression of AS was defin-
ed as an average annual increase of the AV Vmax ≥0.20 m/sec/ 
year because the mean increase of the peak aortic jet velocity 
was 0.14 m/sec/year in the SEAS trial, which included 1,873 
patients with mild-to-moderate AS.
Follow-up
The follow-up was completed and the data was collected un-
til December 2009 during each patient’s annual visit to the 
echocardiographic laboratory and by a detailed review of all 
the medical records and telephone interviews. Deaths were 
classified as cardiac or non-cardiac, based on the medical re-
cords. The endpoint of the study was defined as cardiac death 
or AV replacement (AVR) during follow-up. The progression 
of AS was monitored by the change of the AV Vmax on the 
annual echocardiographic follow-up.
Statistical methods
The continuous variables were compared using Student’s t-
test or the Wilcoxon rank sum test, and categorical variables 
were compared using the Chi-squared test or Fisher’s exact 
test, as appropriate. Cumulative event curves were generated 
using the Kaplan-Meier method. Linear regression analysis 
was used to investigate the relationship between the continu-
ous variables. Stepwise multiple regression analysis was em-
ployed to identify the independent predictors of AS progres-
sion. A univariate probability value threshold of 0.10 was set 
for entry into the equation. All the p-values were two-sided, 
and a p<0.05 was considered significant. All the statistical an-
alyses were performed using Statistical Package for the Social 
Sciences (SPSS) version 12.0 for Windows (SPSS Inc., Chica-
go, IL, USA).
Results
Baseline characteristics
The etiology of AS was degenerative in 73 (70.9%) patients, 
rheumatic in 15 (14.6%) and bicuspid in 12 (11.7%). Fifty-six 
patients (54.4%) had hypertension, 4 (3.9%) had diabetes and 
7 (6.8%) were current smokers. Forty-five patients (43.7%) 
had serum cholesterol concentrations >200 mg/dL and 44 
(42.7%) had moderate-to-severe calcification of the AV. 
Clinical and echocardiographic follow-up
During a median clinical follow-up time of 7.3 years (in-
terquartile range: 6.6-8.4 years), there were two non-cardiac 
deaths and two cardiac events (both AVRs). The estimated 
7-year cardiac event-free survival rate was 98±1%. One pa-
tient underwent AVR because of developing severe symptom-Jeong-Sook Seo, et al.   651
atic AS, and one patient who underwent coronary artery by-
pass grafting combined with AVR because of the presence of 
severe AS. The causes of the two non-cardiac deaths were res-
piratory failure and suicide. 
During a median echocardiographic follow-up time of 6.0 
years (IQR: 4.4-6.5 years), the mean AV Vmax increased from 
2.3±0.3 m/sec to 2.7±0.7 m/sec with an average annual in-
crease of 0.08±0.10 m/sec/year. The annual increase in the 
AV Vmax was significantly related to the initial AV Vmax (r= 
0.379, p<0.001) and age (r=0.252, p=0.011) (Fig. 1). On the 
stepwise multiple regression analysis, age, the baseline AV 
Vmax and moderate-to-severe calcification were the indepen-
dent predictors of the annual progression rate (r=0.570, p< 
0.001). 
 
Relationship between the patient outcomes and the 
rate of progression
Rapid progression, defined as a ≥0.2 m/sec per year incre-
ase in the AV Vmax, was observed in 16 of 103 patients 
(15.5%) and slow progression (<0.2 m/sec per year) was ob-
served in 87 patients (84.5%). The clinical and echocardio-
graphic characteristics of these two groups are compared in 
Table 1 and 2. There were no significant between-group dif-
ferences in age, gender, a history of diabetes or hypertension, 
the level of serum cholesterol, the LV dimensions, the LV 
mass index, the LV EF or the etiology of AS. However, the 
baseline AV Vmax (2.6±0.3 m/sec vs. 2.2±0.3 m/sec, respec-
tively, p<0.001) and the incidence of moderate-to-severe AV 
calcification (92.9% vs. 36.5%, p<0.001) were significantly 
higher in the rapid progression group than in the slow pro-
gression group. Eight patients (50%) in the rapid progres-
sion group developed severe AS (AV Vmax ≥4.0 m/sec or AV 
area ≤0.75 cm
2) during follow-up, and the 7-year cardiac ev-
ent-free survival rate was lower in the rapid progression gr-
oup than in the slow progression group (87.5±8.3% vs. 100%, 
respectively). 
Discussion
We found that asymptomatic patients with mild valvular 
AS and who were prospectively followed-up by repeated echo-
cardiography generally had a benign long-term prognosis 
and slow progression of AS. However, there was marked in-
dividual variability, and progression to severe AS was ob-
served in 50% of the patients with rapid progression of AS. 
The outcomes of the patients with mild and moderate AS 
Table 1. Baseline clinical characteristics
All patients (n=103) Rapid progression (n=16) Slow progression (n=87) p
Age, years 062.1±11.9 066.7±11.8 061.2±11.8 0.090
Male, n (%) 31 (30.1) 06 (37.5) 25 (28.7) 0.556
Body surface area (m
2) 1.7±0.2 01.7±0.2 01.6±0.1 0.801
Current smoker, n (%) 7 (6.8) 03 (21.4) 4 (5.3) 0.165
Diabetes mellitus, n (%) 4 (3.9) 0 (0)0 4 (5.3) 1.000
Hypertension, n (%) 56 (54.4) 10 (62.5) 46 (52.9) 0.589
Hypercholesterolemia, n (%) 45 (43.7) 08 (50.0) 37 (42.5) 0.596
Total cholesterol (mg/dL) 194.4±41.3 204.6±38.9 192.5±41.6 0.282
LDL-cholesterol (mg/dL) 139.8±25.4 135.5±2.12 141.2±29.9 0.358
Use of statin, n (%) 43 (41.7) 06 (37.5) 37 (42.5) 0.664
Atrial fibrillation 14 (13.6) 1 (6.3) 13 (14.9) 0.691
p: Rapid versus Slow progression group, LDL: low density lipoprotein
Fig. 1. Association between the patients’ age, the baseline aortic jet velocity and the annual change in the aortic jet velocity.
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have been reported to be worse than commonly assumed, 
indicating a need to consider rapid progression as predictive 
of excess mortality. The present study, which included only 
patients with mild AS and it excluded those with coronary, 
cerebral and/or peripheral vascular disease, showed that pa-
tients had a more benign natural history than was seen in a 
previous study.
10) The cited works, which included patients 
with moderate-to-severe AS, found that the average rate of 
increase in the mean pressure gradient was about 8 mm Hg 
per year, the average decrease in the AV area was about 0.1 cm
2 
per year and the average rate of increase in the aortic jet maxi-
mum velocity ranged from 0.2 to 0.4 m/sec per year.
5)17-20) We 
found that the average annual increase in the AV Vmax (0.08± 
0.10 m/sec/year) was lower than the 0.14±0.14 m/sec/year 
observed in the SEAS trial, which included patients with mild 
and moderate AS. This finding was similar compared with the 
recent data of mild AS in Korean patients.
21) Our results sug-
gest that more conservative approaches are needed for pa-
tients with mild AS.
We also found that the patient’s age, the baseline AV jet ve-
locity and the presence of moderate-to-severe calcification 
were independent predictors of AS progression. Previous stu-
dies have also reported that significant AV calcification, the 
peak aortic jet velocity and the rapid progression of AS were 
independent predictors of the outcomes for patients with 
mild and moderate AS. Our finding, that AV calcification was 
associated with a poor outcome, confirms the results of a stu-
dy that utilized electron beam tomography to assess the de-
gree of AV calcification.
22) Our results suggest that echocardio-
graphic observation alone is sufficient for patients with mild 
AS, but rapid progression is a risk factor for progressing to se-
vere AS. Follow-up echocardiographic examinations of older 
patients and those with moderate-to-severe calcification or a 
higher baseline aortic jet velocity should be performed to de-
tect rapid progression before severe symptoms occur. 
Although AS was previously regarded as a degenerative ch-
ange, this process is now recognized as sharing many histo-
logic features with atherosclerosis and to be associated with 
the same risk factors.
3)23)24) Thus, degenerative AS is currently 
regarded as an active disease similar to atherosclerosis, and 
it is progressive. Following the finding that hypercholester-
olemia may be a risk factor for AS,
25) several studies have as-
sessed the effects of lipid-lowering therapy for halting or de-
laying progression of the disease.
5)6)17-20) However, it is not 
clear if hypercholesterolemia affects the progression of mild 
AS, and we found that the serum cholesterol concentration 
was not associated with the annual increase of the aortic jet 
velocity even in patients with mild AS. 
 
Limitations
The study patients were enrolled at a tertiary referral hospi-
tals and the gender ratio, the incidence of hypertension and 
the LVMI might be different from other cohort studies. The 
number of study patients was not large enough to detect weak 
correlation between the cholesterol levels and progression 
rates, and to perform subgroup analysis with statistical test-
ing of interactions according to the etiology of AS. The AV 
area was not measured in all the study patients because the 
progression of AS was monitored by the changes in the AV 
Vmax on the follow-up echocardiographic examinations. In 
addition, the predictors of the clinical outcomes could not be 
evaluated due to the very low rate of cardiac events in the pa-
tients with mild AS. 
Conclusion
We have shown here that the progression of AS was slow-
Table 2. Baseline echocardiographic characteristics
All patients (n=103) Rapid progression (n=16) Slow progression (n=87) p
End-systolic LV dimension (mm) 29.9±5.3 28.8±5.2 30.1±5.3 0.349
End-diastolic LV dimension (mm) 49.1±5.3 48.9±5.5 49.2±5.3 0.831
LV mass index (g/m
2) 136.6±41.5 143.5±51.9 133.8±36.9 0.484
Ejection fraction (%) 63.0±6.1 64.4±4.7 62.8±6.3 0.314
Etiology, n (%) 0.711
Degenerative 73 (70.9) 12 (80.0) 61 (70.9)
Bicuspid 12 (11.7) 02 (13.3) 10 (11.6)
Rheumatic 15 (14.6) 1 (6.7) 14 (16.3)
Calcification, n (%) <0.001
None-to-mild 55 (53.4) 1 (7.1) 54 (63.5)
Moderate-to-severe 44 (42.7) 13 (92.9) 31 (36.5)
Aortic valve
Peak velocity (m/sec) 02.3±0.3 02.6±0.3 02.2±0.3 <0.001
Mean pressure gradient (mm Hg) 13.4±3.8 16.0±2.4 12.6±3.8 0.009
p: Rapid versus Slow progression group, LV: left ventricularJeong-Sook Seo, et al.   653
er than expected, and it was related to age, the baseline aor-
tic jet velocity and AV calcification, but not with the serum 
cholesterol concentration in patients with mild AS. Because of 
the marked individual variability in the progression of AS, the 
patients showing rapid progression need close, regular fol-
low-up.
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